Workflow
Autonomix Medical, Inc. Granted New U.S. Patent for Innovative Catheter-Based Platform Technology
Globenewswire· 2025-06-27 20:00
Patent supports the Company’s broader mission to advance minimally invasive, nerve-focused treatments across high-need indications Strengthens strategic position in a multi-billion-dollar market opportunity and expands Autonomix’s growing global IP portfolio with over 80 issued patents THE WOODLANDS, TX, June 27, 2025 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company dedicated to advancing precision nerve-targeted treatments, today announced ...
Abacus Global Management Announces Intention to Conduct Exchange Offer and Consent Solicitation Relating to Warrants
Globenewswire· 2025-06-27 20:00
文章核心观点 公司宣布对未偿还的公共认股权证和私募认股权证进行交换要约和同意征集 [1] 交换要约和同意征集相关 - 公司将向认股权证持有人提供机会,每交出一份未偿还认股权证可换0.23股普通股 [2] - 公司同时将征集认股权证持有人同意修订认股权证协议,使要约结束时仍未行使的每份认股权证可换0.207股普通股,该比例比要约适用的交换比例低10% [2] - 依据认股权证协议条款,除特定修改或修订外,需至少50%未偿还公共认股权证持有人投票或书面同意 [2] 要约启动安排 - 公司预计在提交阐述要约条款的S - 4表格注册声明后启动要约 [3]
AYR Wellness Provides Update on Q1 2025 Interim Filings
Globenewswire· 2025-06-27 20:00
MIAMI, June 27, 2025 (GLOBE NEWSWIRE) -- AYR Wellness Inc. (CSE: AYR.A, OTCQX: AYRWF) (“AYR” or the “Company”), a leading vertically integrated U.S. multi-state cannabis operator, provides an update regarding the status of its interim financial statements, management’s discussion and analysis, and related CEO and CFO certificates for the three-month period ended March 31, 2025 (collectively, the “Interim Filings”).‎ As previously disclosed, the Company’s delay in completing the Interim Filings is primarily ...
Jupiter Neurosciences Unveils Nugevia™ GLO: A Breakthrough in Cellular Skin Health, Backed by Patented Pharmaceutical Science
Globenewswire· 2025-06-27 20:00
GLO targets the growing ”beauty-from-within” market with scientifically proven cellular defense and skin vitality benefits Jupiter, Florida, June 27, 2025 (GLOBE NEWSWIRE) -- Jupiter Neurosciences, Inc. (NASDAQ: JUNS) ("Jupiter" or the "Company"), a clinical-stage pharmaceutical company developing JOTROL™, a proprietary resveratrol-based platform, is pleased to unveil Nugevia™ GLO—a pioneering "beauty-from-within" supplement designed to elevate the standard of skin health through clinically validated cellul ...
Captivision and digiLED Complete Phase One of Landmark LED Installations at Canary Wharf
Globenewswire· 2025-06-27 20:00
Strategic Partnership Accelerates Global Growth TrajectoryMIAMI and LONDON, June 27, 2025 (GLOBE NEWSWIRE) -- Captivision Inc. (“Captivision” or the “Company”) (NASDAQ: CAPT), a pioneering manufacturer and global LED solution provider, a leading innovator in digital display technology and immersive media, today announced the successful completion of the first project phase of a multi-phase LED signage installation project in partnership with digiLED and Canary Wharf Group. This first phase marks a major mil ...
ERES Announces Timing of Second Quarter 2025 Results & Conference Call
Globenewswire· 2025-06-27 20:00
TORONTO, June 27, 2025 (GLOBE NEWSWIRE) -- European Residential Real Estate Investment Trust ("ERES") (TSX:ERE.UN) announced today it will issue its financial results for the three and six months ended June 30, 2025 after markets close on: Wednesday, August 6, 2025 A conference call to discuss the results will be hosted by the ERES senior management team on: Thursday, August 7, 2025 at 9:00 am ET The telephone numbers for the conference call are: Canadian Toll Free: +1 (833) 950-0062 International: +1 (929 ...
180 Degree Capital Corp. Amends Election of Director Special Meeting Date Pursuant to Shareholder Demand Under New York Business Law
Globenewswire· 2025-06-27 20:00
MONTCLAIR, N.J., June 27, 2025 (GLOBE NEWSWIRE) -- 180 Degree Capital Corp. (NASDAQ:TURN) (“180 Degree Capital”) today provides notice to its shareholders that the date of the previously announced special meeting of shareholders for the sole purpose of electing directors (“Director Election Special Meeting”) has been moved to September 15, 2025. This change of date resulted from constructive conversations with the shareholders who submitted a demand request on June 17, 2025 (the “Demand Letter”), who acknow ...
Richtech Robotics and Beijing City of Design Development Sign Agreement to Accelerate Design of Next-Gen AI-Powered Service Robotics
Globenewswire· 2025-06-27 20:00
Collaboration through Joint Venture Boyu AI Technology will advance core software-hardware R&D, vertical market deployment, and industry incubation LAS VEGAS, June 27, 2025 (GLOBE NEWSWIRE) -- Richtech Robotics Inc. (Nasdaq: RR) (“Richtech Robotics” or the “Company”), a Nevada-based provider of AI-driven service robots, today announced the signing of a Strategic Cooperation Agreement with Beijing City of Design Development Co., Ltd. via their Chinese joint venture, Boyu Artificial Intelligence (Beijing) Tec ...
zSpace Unveils Career Explorer Application at ISTELive 25 to Transform Career Readiness
Globenewswire· 2025-06-27 20:00
New AR/VR application empowers students to explore high-demand careers for the 2025–2026 school yearSAN JOSE, Calif., June 27, 2025 (GLOBE NEWSWIRE) -- zSpace (NASDAQ: ZSPC) (“zSpace” or the “Company”), a leader in immersive learning, invites educators and edtech innovators to Booth #1948 at ISTELive 25, held June 30–July 2 at the Henry B. González Convention Center. Attendees will experience the preview of the zSpace Career Explorer™ application, a groundbreaking augmented and virtual reality (AR/VR) tool ...
Lyra Therapeutics Announces Up to Approximately $15 Million Registered Direct Offering and Concurrent Private Placement Priced At-The-Market Under Nasdaq Rules
Globenewswire· 2025-06-27 20:00
文章核心观点 临床阶段生物技术公司Lyra Therapeutics宣布进行注册直接发行和私募配售,预计获得约500万美元毛收入,若私募认股权证全部现金行使,公司将额外获得约980万美元毛收入,所得款项用于营运资金和一般公司用途 [1][3][4] 交易详情 - 公司签订协议,在注册直接发行中出售423,372股普通股(或预融资认股权证),同时私募配售可购买多达846,744股普通股的认股权证,普通股(或预融资认股权证)和相关私募认股权证的组合有效购买价为每股11.81美元,私募认股权证行使价为每股11.56美元,可立即行使,有效期24个月 [1] - H.C. Wainwright & Co.担任此次发行的独家配售代理 [2] 发行时间与收益 - 发行预计于2025年6月27日左右完成,需满足惯例成交条件,发行给公司带来的毛收入预计约为500万美元,扣除配售代理费和其他发行费用前 [3] - 若私募认股权证持有人全部现金行使认股权证,公司将额外获得约980万美元毛收入,扣除配售代理费前,但公司无法预测认股权证是否或何时会被行使 [4] 资金用途 公司打算将发行所得净收益用于营运资金和其他一般公司用途,包括LYR - 210的潜在临床开发、制造和其他商业化前费用 [3] 发行相关文件 - 注册直接发行的证券根据先前提交并于2024年4月1日生效的S - 3表格上架注册声明发售,发行仅通过构成注册声明一部分的招股说明书补充文件进行,相关招股说明书补充文件将由公司提交给美国证券交易委员会 [5] - 私募配售的认股权证和行使认股权证可发行的股份根据1933年《证券法》第4(a)(2)条和/或相关法规D进行私募,未根据该法或适用州证券法注册,除非注册或有适用的注册豁免,否则不得在美国发售或出售 [6] 联系方式 - 首席财务官Jason Cavalier,电话917.584.7668,邮箱jcavalier@lyratx.com [10] - The Yates Network LLC的Kathryn Morris,电话914.204.6412,邮箱kathryn@theyatesnetwork.com [10]